[go: up one dir, main page]

WO2009091826A3 - Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) - Google Patents

Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) Download PDF

Info

Publication number
WO2009091826A3
WO2009091826A3 PCT/US2009/030998 US2009030998W WO2009091826A3 WO 2009091826 A3 WO2009091826 A3 WO 2009091826A3 US 2009030998 W US2009030998 W US 2009030998W WO 2009091826 A3 WO2009091826 A3 WO 2009091826A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
compositions
methods related
car
specific chimeric
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/030998
Other languages
French (fr)
Other versions
WO2009091826A2 (en
WO2009091826A9 (en
Inventor
Laurence J.N. Cooper
Pallavi Manuri
Simon Olivares
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
University of Texas at Austin
Original Assignee
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System, University of Texas at Austin filed Critical University of Texas System
Publication of WO2009091826A2 publication Critical patent/WO2009091826A2/en
Publication of WO2009091826A9 publication Critical patent/WO2009091826A9/en
Publication of WO2009091826A3 publication Critical patent/WO2009091826A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Embodiments of the invention include compositions and methods related to a human CD19-specific chimeric T cell receptor polypeptide comprising an intracellular signaling domain, a transmembrane domain and an extracellular domain, the extracellular domain comprising a human CD 19 binding region.
PCT/US2009/030998 2008-01-14 2009-01-14 Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) Ceased WO2009091826A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2099108P 2008-01-14 2008-01-14
US61/020,991 2008-01-14

Publications (3)

Publication Number Publication Date
WO2009091826A2 WO2009091826A2 (en) 2009-07-23
WO2009091826A9 WO2009091826A9 (en) 2009-09-24
WO2009091826A3 true WO2009091826A3 (en) 2009-11-19

Family

ID=40885876

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/030998 Ceased WO2009091826A2 (en) 2008-01-14 2009-01-14 Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)

Country Status (1)

Country Link
WO (1) WO2009091826A2 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10287606B2 (en) 2015-11-04 2019-05-14 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10858628B2 (en) 2015-11-04 2020-12-08 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11007224B2 (en) 2012-05-25 2021-05-18 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US11014989B2 (en) 2015-01-26 2021-05-25 Cellectis Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994298B2 (en) 2004-09-24 2011-08-09 Trustees Of Dartmouth College Chimeric NK receptor and methods for treating cancer
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US8859229B2 (en) 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US12492376B2 (en) 2009-10-29 2025-12-09 The Trustees Of Dartmouth College T-cell receptor-deficient T cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2826942C (en) * 2011-02-11 2021-08-03 Memorial Sloan-Kettering Cancer Center Hla-restricted, peptide-specific antigen binding proteins
JP6082997B2 (en) 2011-04-01 2017-02-22 メモリアル スローン−ケタリング キャンサー センター T cell receptor-like antibody to WT1 peptide presented by HLA-A2
CN102735841B (en) * 2011-04-13 2014-11-05 苏州卫生职业技术学院 Method for detecting content of soluble CD28 in blood of patients suffering Graves disease
GB201108236D0 (en) * 2011-05-17 2011-06-29 Ucl Business Plc Method
US9193595B2 (en) 2011-06-21 2015-11-24 Drexel University Compositions comprising free-standing two-dimensional nanocrystals
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
SG11201400527XA (en) 2011-09-16 2014-04-28 Univ Pennsylvania Rna engineered t cells for the treatment of cancer
CA2863799C (en) 2012-02-22 2020-09-01 Matthew J. FRIGAULT Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
CA3209571A1 (en) * 2012-03-23 2013-09-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mesothelin chimeric antigen receptors
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
WO2013169691A1 (en) * 2012-05-07 2013-11-14 Trustees Of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
CN103483452B (en) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 Dual-signal-independent chimeric antigen receptors and their uses
US20140120136A1 (en) * 2012-10-12 2014-05-01 The Babraham Institute Mir-155 enhancement of cd8+ t cell immunity
ES2718903T3 (en) * 2012-10-24 2019-07-05 Us Health M971 chimeric antigen receptors
US20150320799A1 (en) * 2012-12-20 2015-11-12 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
JP6420776B2 (en) * 2013-03-05 2018-11-07 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ Engager cells for immunotherapy
WO2014138314A1 (en) * 2013-03-05 2014-09-12 Baylor College Of Medicine Oncolytic virus
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
US9790282B2 (en) * 2013-03-25 2017-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
DK2981607T3 (en) 2013-04-03 2020-11-16 Memorial Sloan Kettering Cancer Center EFFICIENT GENERATION OF TUMOR-TARGETED T-CELLS DERIVED FROM PLURIPOTENT STEM CELLS
CN104140974B (en) * 2013-05-08 2017-09-29 科济生物医药（上海）有限公司 Nucleic acid encoding GPC‑3 chimeric antigen receptor protein and T lymphocytes expressing GPC‑3 chimeric antigen receptor protein
RS65484B1 (en) * 2013-05-13 2024-05-31 Cellectis Cd19 specific chimeric antigen receptor and uses thereof
KR102238226B1 (en) 2013-05-14 2021-04-09 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Human application of engineered chimeric antigen receptor (car) t-cells
WO2014190273A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
AU2014342020C1 (en) * 2013-10-31 2019-09-05 Fred Hutchinson Cancer Research Center Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof
KR102375998B1 (en) 2014-02-14 2022-03-21 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 Chimeric antigen receptors and methods of making
AP2016009438A0 (en) 2014-02-25 2016-09-30 Achillion Pharmaceuticals Inc Aryl, heteroaryl, and heterocyclic compounds for treatment of complement mediated disorders
WO2015142675A2 (en) * 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
FI3888674T3 (en) 2014-04-07 2024-07-02 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
SG11201608393TA (en) 2014-04-10 2016-11-29 Seattle Children S Hospital Dba Seattle Children S Res Inst Transgene genetic tags and methods of use
KR20160145802A (en) * 2014-04-23 2016-12-20 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Chimeric antigen receptors (car) for use in therapy and methods for making the same
US11400115B2 (en) 2014-04-23 2022-08-02 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
SI3689899T1 (en) 2014-04-25 2022-01-31 2Seventy Bio, Inc. MND promoter of chimeric antigen receptors
EP3738597A1 (en) 2014-04-25 2020-11-18 Bluebird Bio, Inc. Improved methods for manufacturing adoptive cell therapies
AU2015270912B9 (en) 2014-06-02 2021-01-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting CD-19
NZ726989A (en) 2014-06-06 2020-08-28 Bluebird Bio Inc Improved t cell compositions
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
SG10201900455YA (en) 2014-07-24 2019-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
TWI805109B (en) * 2014-08-28 2023-06-11 美商奇諾治療有限公司 Antibodies and chimeric antigen receptors specific for cd19
EP3197832B1 (en) 2014-09-25 2022-06-22 Drexel University Physical forms of mxene materials exhibiting novel electrical and optical characteristics
CN106973568B (en) 2014-10-08 2021-07-23 诺华股份有限公司 Biomarkers for predicting therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
HK1243441A1 (en) * 2014-11-05 2018-07-13 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
IL278574B2 (en) 2014-11-12 2024-11-01 Seagen Inc Compounds acting on glycans and methods of using them
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
NZ733025A (en) 2014-12-12 2022-01-28 2Seventy Bio Inc Bcma chimeric antigen receptors
US10538431B2 (en) 2015-03-04 2020-01-21 Drexel University Nanolaminated 2-2-1 MAX-phase compositions
IL254817B2 (en) 2015-04-08 2023-12-01 Novartis Ag CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cells
WO2017011044A2 (en) 2015-04-20 2017-01-19 Drexel University Two-dimensional, ordered, double transition metals carbides having a nominal unit cell composition m'2m"nxn+1
US11173179B2 (en) 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US11655452B2 (en) 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
CA2986705A1 (en) 2015-07-16 2017-01-19 Biokine Therapeutics Ltd. A cxcr4 inhibitor and a pdi antagonist for use in treating cancer
US11458167B2 (en) 2015-08-07 2022-10-04 Seattle Children's Hospital Bispecific CAR T-cells for solid tumor targeting
EP3340982B1 (en) 2015-08-26 2021-12-15 Achillion Pharmaceuticals, Inc. Compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
AR105808A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc AMIDA COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035351A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of medical disorders
AR105809A1 (en) 2015-08-26 2017-11-08 Achillion Pharmaceuticals Inc COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035362A1 (en) * 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Use of complement pathway inhibitor compounds to mitigate adoptive t-cell therapy associated adverse immune responses
WO2017035361A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Disubstituted compounds for the treatment of medical disorders
US10000516B2 (en) 2015-08-26 2018-06-19 Achillion Pharmaceuticals, Inc. Phosphonate compounds for treatment of medical disorders
WO2017035355A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Ether compounds for treatment of medical disorders
AR106018A1 (en) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc ARYL, HETEROARYL AND HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3340983B1 (en) 2015-08-26 2023-10-04 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
US11747346B2 (en) 2015-09-03 2023-09-05 Novartis Ag Biomarkers predictive of cytokine release syndrome
CN109824778B (en) * 2015-09-18 2022-07-19 上海科济制药有限公司 anti-CD 19 fully human antibodies and immune effector cells targeting CD19
WO2017083582A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11479755B2 (en) 2015-12-07 2022-10-25 2Seventy Bio, Inc. T cell compositions
EP3419645B1 (en) 2016-02-23 2020-09-02 BioLineRx Ltd. Method of selecting a treatment regimen in acute myeloid leukemia (aml)
JP7282521B2 (en) 2016-04-08 2023-05-29 パーデュー・リサーチ・ファウンデイション Methods and compositions for CAR T cell therapy
EP4353750A3 (en) 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof
CN107815465B (en) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized gene modified animal model
US11279948B2 (en) 2016-08-31 2022-03-22 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric OX40
EP3523331A1 (en) 2016-10-07 2019-08-14 Novartis AG Chimeric antigen receptors for the treatment of cancer
KR20240005168A (en) 2016-11-04 2024-01-11 2세븐티 바이오, 인코포레이티드 Anti-bcma car t cell compositions
US11261428B2 (en) 2018-03-15 2022-03-01 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
US11332713B2 (en) 2016-11-16 2022-05-17 KSQ Therapeutics, Inc. Gene-regulating compositions and methods for improved immunotherapy
WO2018094143A1 (en) 2016-11-17 2018-05-24 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN110291200B (en) 2016-12-12 2024-05-14 西雅图儿童医院（Dba西雅图儿童研究所） Agent ligand induction of transgene expression in mammalian cells
CN108424928B (en) * 2016-12-30 2021-03-16 百奥赛图(北京)医药科技股份有限公司 Preparation method and application of humanized gene modified animal model
EP3346001A1 (en) * 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
EP4043485A1 (en) 2017-01-26 2022-08-17 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
EP3579870A4 (en) 2017-02-07 2020-12-30 Seattle Children's Hospital (DBA Seattle Children's Research Institute) PHOSPHOLIPID ETHER (PLE) AGENTS TARGETING CAR T CELL TUMOR (CTCT)
WO2018160622A1 (en) 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy
CN110603252A (en) 2017-03-01 2019-12-20 艾其林医药公司 Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
EP3589287B1 (en) 2017-03-01 2022-09-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
KR20240044544A (en) 2017-03-03 2024-04-04 씨젠 인크. Glycan-interacting compounds and methods of use
WO2018170506A1 (en) * 2017-03-17 2018-09-20 University Of Tennessee Research Foundation Methods of using cytotoxic t cells for treatment of autoimmune diseases
CN107058232B (en) * 2017-04-12 2018-03-30 上海优卡迪生物医药科技有限公司 Cholesterol turns repressed CAR T cells of lipase SOAT1 and its preparation method and application
SG11202000555UA (en) 2017-06-21 2020-02-27 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
JP2020530277A (en) 2017-06-30 2020-10-22 セレクティスＣｅｌｌｅｃｔｉｓ Cellular immunotherapy for repeated doses
CA3107910A1 (en) 2017-08-01 2019-02-07 Drexel University Mxene sorbent for removal of small molecules from dialysate
EP3661493A4 (en) 2017-08-02 2021-04-14 Achillion Pharmaceuticals, Inc. Therapeutic regimens for treatment of paroxysmal nocturnal hemoglobinuria
CA3075915A1 (en) 2017-09-15 2019-03-21 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19 immunotherapy
BR112020007576A2 (en) 2017-10-18 2020-09-24 Novartis Ag compositions and methods for selective protein degradation
MX2020004229A (en) * 2017-10-25 2020-07-22 Novartis Ag METHODS OF PRODUCTION OF CELLS THAT EXPRESS CHIMERIC ANTIGENIC RECEPTORS.
AU2019209432A1 (en) 2018-01-22 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of use for CAR T cells
CN111936518A (en) 2018-02-06 2020-11-13 西雅图儿童医院（Dba西雅图儿童研究所） Fluorescein-specific CARs exhibiting optimal T cell function for FL-PLE labeled tumors
CN111094358A (en) 2018-02-11 2020-05-01 江苏恒瑞医药股份有限公司 An isolated chimeric antigen receptor and modified T cells comprising the same and uses
WO2019165237A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
US20240216509A1 (en) * 2018-05-07 2024-07-04 Children's Hospital Medical Center Chimeric polypeptides, nucleic acid molecules, cells, and related methods
US11470424B2 (en) 2018-06-06 2022-10-11 Drexel University MXene-based voice coils and active acoustic devices
AU2019284911A1 (en) 2018-06-13 2020-12-17 Novartis Ag BCMA chimeric antigen receptors and uses thereof
MX2021002640A (en) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Morphic forms of complement factor d inhibitors.
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
EP3856164B1 (en) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
IL283734B2 (en) 2018-12-12 2025-03-01 Kite Pharma Inc Chimeric antigen receptors and car-t cells and methods of use
US12239645B2 (en) 2018-12-17 2025-03-04 Achillion Pharmaceuticals, Inc. Targeted dosing for the treatment of complement mediated disorders
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. CD19 DIRECTED CHIMERIC ANTIGEN RECEPTORS AND THEIR USES IN IMMUNOTHERAPY
JP7635138B2 (en) 2019-03-22 2025-02-25 アキリオン ファーマシューティカルズ， インコーポレーテッド Pharmaceutical compounds for the treatment of complement-mediated disorders
CN112210007B (en) * 2019-07-11 2022-07-12 华夏英泰（北京）生物技术有限公司 A CD19 antigen high-affinity antibody and a chimeric antigen receptor comprising its CD19 single-chain antibody region
CA3163104A1 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
MX2022008648A (en) 2020-01-23 2022-12-15 The Children´S Medical Center Corp DIFFERENTIATION OF T CELLS WITHOUT STROMA FROM HUMAN PLURIPOTENT STEM CELLS.
MX2022010936A (en) 2020-03-05 2022-11-16 Neotx Therapeutics Ltd ³METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH IMMUNE CELLS.
WO2024178397A2 (en) 2023-02-24 2024-08-29 Elevatebio Technologies, Inc. Modified immune effector cells and methods of use
KR20250167107A (en) * 2023-04-07 2025-11-28 엔카르타, 인크. Treatment of autoimmune diseases
CN121079317A (en) 2023-04-28 2025-12-05 深圳深信生物科技有限公司 Modified delivery vehicles and uses thereof
WO2025007073A2 (en) 2023-06-29 2025-01-02 Dispatch Biotherapeutics, Inc. Synthetic cytokine receptors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126363A1 (en) * 2000-11-07 2004-07-01 Jensen Michael C. Cd19-specific redirected immune cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126363A1 (en) * 2000-11-07 2004-07-01 Jensen Michael C. Cd19-specific redirected immune cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
CLAUDIA M. KOWOLIK ET AL.: "CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.", CANCER RES., vol. 66, no. 22, 2006, pages 10995 - 11004 *
LAURENCE J. N. COOPER ET AL.: "Enhanced antilymphoma efficacy of CD19-redirected influenza MPl-specific CTLs by cotransfer of T cells modified to present influenza MP1.", BLOOD., vol. 105, no. 4, 2005, pages 1622 - 1631 *
LAURENCE J. N. COOPER ET AL.: "T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect.", BLOOD, vol. 101, no. 4, 2003, pages 1637 - 1644 *
RENIER J. BRENTJENS ET AL.: "Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.", CLIN. CANCER RES., vol. 13, no. 18, 2007, pages 5426 - 5435 *
TINA MULLER ET AL.: "Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity ofNK cells and overcomes NK-resistance of lymphoma and leukemia cells.", CANCER IMMUNOL. IMMUNOTHER., vol. 57, 24 August 2007 (2007-08-24), pages 411 - 423 *
TONTANAI NUMBENJAPON ET AL.: "Antigen-independent and antigen-dependent methods to numerically expand CD19-specific CD8+ T cells.", EXPERIMENTAL HEMATOLOGY., vol. 35, 2007, pages 1083 - 1090 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11007224B2 (en) 2012-05-25 2021-05-18 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US11077144B2 (en) 2013-05-13 2021-08-03 Cellectis CD19 specific chimeric antigen receptor and uses thereof
US10626372B1 (en) 2015-01-26 2020-04-21 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US12385012B2 (en) 2015-01-26 2025-08-12 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11634688B2 (en) 2015-01-26 2023-04-25 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11014989B2 (en) 2015-01-26 2021-05-25 Cellectis Anti-CLL1 specific single-chain chimeric antigen receptors (scCARs) for cancer immunotherapy
US11072781B2 (en) 2015-11-04 2021-07-27 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US10287606B2 (en) 2015-11-04 2019-05-14 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US11162075B2 (en) 2015-11-04 2021-11-02 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11162076B2 (en) 2015-11-04 2021-11-02 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US11352607B2 (en) 2015-11-04 2022-06-07 Fate Therapeutics, Inc. Genomic engineering of pluripotent cells
US10947505B2 (en) 2015-11-04 2021-03-16 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US10858628B2 (en) 2015-11-04 2020-12-08 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US12410403B2 (en) 2015-11-04 2025-09-09 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
US12491153B2 (en) 2018-01-03 2025-12-09 Qu Biologics Inc. Innate targeting of adoptive cellular therapies

Also Published As

Publication number Publication date
WO2009091826A2 (en) 2009-07-23
WO2009091826A9 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2009091826A3 (en) Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
MY159679A (en) Antibodies binding preferentially human csf1r extracellular domain 4 and their use
WO2017066481A8 (en) Chimeric antigen receptors containing a chlorotoxin domain
WO2019090003A9 (en) Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
WO2017172981A3 (en) Chimeric antigen receptors targeting cancer
WO2010003101A3 (en) Il6 immunotherapeutics
WO2010016766A3 (en) Antibodies recognizing endogenous human lgr5 and/or lgr6
WO2008045437A3 (en) Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
WO2010037041A3 (en) Frizzled-binding agents and uses thereof
MY155621A (en) Axl antibodies
WO2014074532A3 (en) Compositions and methods for modulating cell signaling
WO2009128963A3 (en) Cross-neutralizing human monoclonal antibodies to sars-cov and methods of use thereof
HK1254820A1 (en) Immune checkpoint chimeric antigen receptors therapy
WO2017079694A3 (en) Chimeric antigen receptors targeting her2
WO2012142515A3 (en) Fc fusion proteins comprising novel linkers or arrangements
NZ592420A (en) Cd86 antagonist multi-target binding proteins
WO2016044853A8 (en) Central memory t cells for adoptive t cell therapy
WO2008059252A3 (en) Methods and composition fro t cell receptors which recognize 5t4 antigen
WO2011119979A3 (en) Antibodies to muc16 and methods of use thereof
NZ618129A (en) Compositions of humanized notch fusion proteins and methods of treatment
ATE475669T1 (en) CELLS EXPRESSING A MODIFIED T-CELL RECEPTOR
WO2010008831A3 (en) Compounds and methods for modulating g protein-coupled receptors
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
IL221366A0 (en) SOLUBLE zB7RI POLYPEPTIDE AND METHOD USING IT
WO2008089022A3 (en) Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09702675

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09702675

Country of ref document: EP

Kind code of ref document: A2